Architecture and dynamics of immature HIV lattice
未成熟HIV晶格的结构和动力学
基本信息
- 批准号:10866707
- 负责人:
- 金额:$ 45.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntiviral AgentsArchitectureAtomic Force MicroscopyAwardBindingBiochemicalBiomechanicsCASP1 geneCapsidComputing MethodologiesConeDevelopmentDiffusionDiseaseEnzymesExperimental DesignsFundingFutureGeometryGoalsGuide RNAHIVHIV ProteaseIndividualIntegraseKineticsKnowledgeLinkMeasurementMeasuresMembraneMethodsMicroscopicMolecularNatureOpen Reading FramesPeptide HydrolasesPrevalenceProcessProteinsProteolysisRNA-Directed DNA PolymeraseResidual stateRoleSignal TransductionStructureSystemTestingVertebral columnViralVirionVirusbiophysical techniquescofactordesigndimerequilibration disordergag Gene Productsgag-pol Fusion Proteinsimaging modalityinhibitormonomernext generationpol Gene Products
项目摘要
Project Summary:
Our long-term goal is to gain a molecular understanding of the machinery that regulates the assembly, release,
and maturation of infectious HIV virions. Newly released HIV virions are immature and have a lattice of proteins
(mainly the Gag polyprotein) that underpins their viral membrane. Through proteolysis, HIV enzymes help
transform this lattice into a conical mature core, after which the virus becomes infectious. Maturation Inhibitors,
a new class of antiviral drugs, are designed to bind to the immature lattice and interfere with this transformation.
During the previous award period, we showed that the stability of the immature lattice is dependent on other HIV
components aside from the Gag polyprotein. The small size of HIV virions makes studying their lattice dynamics
challenging, therefore, we developed biophysical, imaging, and computational methods to enable these
measurements. We have two main aims for this award period. Our first aim is to investigate the specific effects
of different non-Gag components on the stability of the immature lattice and determine the nature of biomolecular
forces stabilizing it. Our second aim is to determine how dynamics within the lattice drive the activation of HIV
enzymes and kick start the maturation process. By advancing our understanding of the biomechanical principles
governing the immature lattice of HIV and its maturation, our studies will inform both the design of next-
generation antivirals as well as future lentiviral systems.
项目总结:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Saveez Saffarian其他文献
Saveez Saffarian的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Saveez Saffarian', 18)}}的其他基金
International Retroviral Symposium: Assembly, Maturation and Uncoating
国际逆转录病毒研讨会:组装、成熟和脱壳
- 批准号:
10762858 - 财政年份:2023
- 资助金额:
$ 45.23万 - 项目类别:
Dynamics of Gag-Pol auto-processing and ESCRT recruitment during HIV budding
HIV 萌芽期间 Gag-Pol 自动处理和 ESRT 招募的动态
- 批准号:
10222521 - 财政年份:2017
- 资助金额:
$ 45.23万 - 项目类别:
Dynamics of Gag-Pol auto-processing and ESCRT recruitment during HIV budding
HIV 萌芽期间 Gag-Pol 自动处理和 ESRT 招募的动态
- 批准号:
9411628 - 财政年份:2017
- 资助金额:
$ 45.23万 - 项目类别:
Dynamics of Gag-Pol auto-processing and ESCRT recruitment during HIV budding
HIV 萌芽期间 Gag-Pol 自动处理和 ESRT 招募的动态
- 批准号:
10405685 - 财政年份:2017
- 资助金额:
$ 45.23万 - 项目类别:
Dynamics of early ESCRT recruitment during HIV budding
HIV 萌芽期间早期 ESRT 招募的动态
- 批准号:
8790376 - 财政年份:2014
- 资助金额:
$ 45.23万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 45.23万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 45.23万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 45.23万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 45.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 45.23万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 45.23万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 45.23万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 45.23万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 45.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 45.23万 - 项目类别:














{{item.name}}会员




